All issues > Volume 49(8); 2006

Original Article

Korean J Pediatr. 2006;49(8):864-869. Published online August 15, 2006.

Immunogenicity and safety of enhanced-inactivated poliovaccine(eIPV) in healthy Korean infants

Jung Soo JS Kim¹, Young Jin YJ Hong², Jong Duk JD Kim³, Young Taek YT Jang⁴, Jin Han JH Kang⁵

¹Department of Pediatrics, Chonbuk National University Medical School, Chonbuk
²Department of Pediatrics, College of Medicine, Inha University, Incheon
³Department of Pediatrics, Scool of Medicine, Wonkwang University, Chonbuk
⁴Department of Pediatrics, Jeonju Presbyterian Medical Center, Jeonju
⁵Department of Pediatrics, College of Medicine, The Catholic University of Korea

Correspondence Jung Soo JS Kim ,Email: kimjsp@chonbuk.ac.kr

Abstract

Purpose
: We evaluated the immunogenicity and safety of eIPV(Imovax PolioⓇ) in a group of healthy Korean infants on a three-dose primary vaccination.
Methods
: Eighty one healthy infants aged 8-10 weeks were enrolled, and 79(male 42, female 37) completed the study. Three doses of eIPV were injected intramuscularly at 2, 4 and 6 months of age as of primary vaccination. Most subjects received concomitant vaccines such as DTaP and/or Hib at 2, 4, and 6 months of age. Immediate reactions were monitored for 30 minutes after each injection. Local and systemic events were recorded for 72 hours following each immunization by parents/ guardians. Poliovirus specific neutralizing antibodies were measured using enzyme immuno-assay (EIA) at prior to and 1 month after the third dose. An antibody titer of 1:8 or higher was considered seroprotective. Geometric mean titers(GMTs) to each poliovirus type antigen were also measured.
Results
: One month after the third dose of eIPV, all infants(100 percent) were seroprotective. The geometric mean titers(GMTs) were 1,532(95 percent CI : 1,312-1,788) in type 1 and 835(95 percent CI : 684-1,018) in type 2 and 846(95 percent CI : 692-1,035) in type 3. Overall, local reactions were observed in 10 percent of infants and systemic reactions in 26.2 percent of infants. All reactions were observed within 3 days after vaccination and resolved without treatment.
Conclusion
: eIPV(Imovax PolioⓇ) is a well-tolerated and highly immunogenic vaccine. It can be administered either alone or simultaneously with other routine vaccines to Korean infants.

Keywords :Poliomyelitis , eIPV , Vaccine , Immunogenicity , Adverse reaction